The San Diego-based firm emerged from stealth mode with a plan to develop technologies to improve the quality and reduce the cost of genetic analysis.
The company said it will use the funding to accelerate the launch of its core isotachophoresis platform for nucleic acid sample preparation.
With $46 million in total raised since its founding in 2016, the company hopes to scale its telegenetics services to meet national demand.
The firm will use the funding for working capital for the Cyto-Mine single-cell analysis platform, UK facility expansion, and a new US sales office and demo lab.
The company is commercializing a method developed by researchers at Johns Hopkins that detects cancer with high specificity from a blood sample.
The company plans to use the funds to support further commercialization of its tumor tissue sequencing test, the Paradigm Cancer Diagnostic.
The firm will use the proceeds to scale operations, advance its companion diagnostics program, and further expand its minimal residual disease program.
The company will use the funds to expand its operations across the US, Europe, and Asia as well as to support the launch of new single-cell protein assays.
The BGI Group subsidiary said it plans to strengthen its R&D and instrument production, targeting a global sequencing market it expects to grow to $12.45 billion in 2022.
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.
Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.
Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.
In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.